EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with t...
Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an...
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding a...
Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautious
Novo Nordisk (NYSE:NVO) delivered promising data over the weekend for its next-generation weight-loss injection, CagriSema, showing it can achieve weight reductions on par with the most effective t...
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, inc...
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published ...
Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational C...
Novo Nordisk And Its Real Value
Novo Nordisk remains fundamentally strong with robust earnings growth, high ROE, ROIC, and gross margins, despite recent CEO change and short-term market concerns. The stock appears undervalued, tr...
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to...
Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Novo Nordisk's experimental drug results in up to 24% weight loss
Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company ...
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full resul...
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Novo Nordisk: The Strength To Withstand Challenges
Novo Nordisk's price has regained momentum in recent weeks after seeing a big slump earlier in 2025. With strong financials, and robust profit estimates even after a downgrade in outlook, NVO could...
The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars
Novo Nordisk's annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.
Novo Nordisk: The Time To Buy Has Come
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient inves...
Novo Nordisk Stock: Is It Still a Smart Buy?
Much like the long-term users of its most popular product, Novo Nordisk's (NVO 0.69%) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss...
Related Companies